OR WAIT 15 SECS
September 17, 2015.
The global ischemic heart disease (IHD) drugs market is to grow at a CAGR of 3.61% during 2014-2019, according to a report from Resarch and Markets.
According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases (CVDs). People with diabetes are three to four times more likely to develop CVDs than people without diabetes.
AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer, and Sanofi will dominate the market, states the report, although the availability of effective surgical treatments and the use of catheter based interventions will pose a challenge to market growth.